• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by CVRx Inc. (Amendment)

    1/19/24 9:24:56 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care
    Get the next $CVRX alert in real time by email
    SC 13D/A 1 d736880dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(a)

    (Amendment No. 2)*

     

     

    CVRx, Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

    126638105

    (CUSIP number)

    Edwin de Graaf

    Cooperatieve Gilde Healthcare IV U.A.

    Stadsplateau 36

    3521 AZ Utrecht

    The Netherlands

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    January 17, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.  ☐.

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 126638105    13D    Page 1 of 9 Pages

     

      1    

      NAMES OF REPORTING PERSON

      Cooperatieve Gilde Healthcare IV U.A.

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS*

     

      WC

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      The Netherlands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      1,368,206 (1)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      1,368,206 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,368,206 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      6.6% (2)

    14  

      TYPE OF REPORTING PERSON*

     

      OO

     

    (1)

    Includes options exercisable within 60 days of January 17, 2024. All shares are held of record by Cooperatieve Gilde Healthcare IV U.A. (“Gilde Healthcare”). Gilde Healthcare IV Management B.V. is the manager of Gilde Healthcare and may be deemed to have voting, investment and dispositive power with respect to these securities. Gilde Healthcare IV Management B.V. is fully owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director).

    (2)

    Based on 20,815,635 shares of common stock outstanding of CVRx, Inc. (the “Issuer”), as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on October 31, 2023.


    CUSIP NO. 126638105    13D    Page 2 of 9 Pages

     

      1    

      NAMES OF REPORTING PERSON

      Gilde Healthcare IV Management B.V.

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS*

     

      AF

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      The Netherlands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      1,368,206 (1)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      1,368,206 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,368,206 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      6.6% (2)

    14  

      TYPE OF REPORTING PERSON*

     

      OO

     

    (1)

    Includes options exercisable within 60 days of January 17, 2024. All shares are held of record by Cooperatieve Gilde Healthcare IV U.A. (“Gilde Healthcare”). Gilde Healthcare IV Management B.V. is the manager of Gilde Healthcare and may be deemed to have voting, investment and dispositive power with respect to these securities. Gilde Healthcare IV Management B.V. is fully owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director).

    (2)

    Based on 20,815,635 shares of common stock outstanding of CVRx, Inc. (the “Issuer”), as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on October 31, 2023.


    CUSIP NO. 126638105    13D    Page 3 of 9 Pages

     

      1    

      NAMES OF REPORTING PERSON

      Gilde Healthcare Holding B.V.

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS*

     

      AF

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      The Netherlands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      1,368,206 (1)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      1,368,206 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,368,206 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      6.6% (2)

    14  

      TYPE OF REPORTING PERSON*

     

      OO

     

    (1)

    Includes options exercisable within 60 days of January 17, 2024. All shares are held of record by Cooperatieve Gilde Healthcare IV U.A. (“Gilde Healthcare”). Gilde Healthcare IV Management B.V. is the manager of Gilde Healthcare and may be deemed to have voting, investment and dispositive power with respect to these securities. Gilde Healthcare IV Management B.V. is fully owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director).

    (2)

    Based on 20,815,635 shares of common stock outstanding of CVRx, Inc. (the “Issuer”), as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on October 31, 2023.


    CUSIP NO. 126638105    13D    Page 4 of 9 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Manapouri B.V. (100% owned by Edwin de Graaf)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS*

     

      AF

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      The Netherlands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      1,368,206 (1)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      1,368,206 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,368,206 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      6.6% (2)

    14  

      TYPE OF REPORTING PERSON*

     

      OO

     

    (1)

    Includes options exercisable within 60 days of January 17, 2024. All shares are held of record by Cooperatieve Gilde Healthcare IV U.A. (“Gilde Healthcare”). Gilde Healthcare IV Management B.V. is the manager of Gilde Healthcare and may be deemed to have voting, investment and dispositive power with respect to these securities. Gilde Healthcare IV Management B.V. is fully owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director).

    (2)

    Based on 20,815,635 shares of common stock outstanding of CVRx, Inc. (the “Issuer”), as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on October 31, 2023.


    CUSIP NO. 126638105    13D    Page 5 of 9 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Martemanshurk B.V. (100% owned by Pieter van der Meer)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS*

     

      AF

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      The Netherlands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      1,368,206 (1)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      1,368,206 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,368,206 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      6.6% (2)

    14  

      TYPE OF REPORTING PERSON*

     

      OO

     

    (1)

    Includes options exercisable within 60 days of January 17, 2024. All shares are held of record by Cooperatieve Gilde Healthcare IV U.A. (“Gilde Healthcare”). Gilde Healthcare IV Management B.V. is the manager of Gilde Healthcare and may be deemed to have voting, investment and dispositive power with respect to these securities. Gilde Healthcare IV Management B.V. is fully owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director).

    (2)

    Based on 20,815,635 shares of common stock outstanding of CVRx, Inc. (the “Issuer”), as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on October 31, 2023.


    CUSIP NO. 126638105    13D    Page 6 of 9 Pages

     

    Explanatory Note

    This Amendment No. 2 (“Amendment No. 2”) to Schedule 13D amends and supplements the Schedule 13D filed on July 12, 2021, as amended by Amendment No. 1 to Schedule 13D filed on December 29, 2023 (as so amended, the “Schedule 13D”), relating to the common stock, par value $0.01 per share (“Common Stock”), of CVRx, Inc., a Delaware corporation (the “Issuer”). This Amendment No. 2 reflects, among other things, the sales of shares of Common Stock by Cooperatieve Gilde Healthcare IV U.A. (“Gilde Healthcare”). Capitalized terms used but not defined in this Amendment No. 2 shall have the same meanings ascribed to them in the Schedule 13D.

    Item 1. Security and Issuer.

    There are no changes to the Item 1 information previously filed.

    Item 2. Identity and Background.

    There are no changes to the Item 2 information previously filed.

    Item 3. Source and Amount of Funds or Other Consideration.

    There are no changes to the Item 3 information previously filed.

    Item 4. Purpose of Transaction.

    Item 4 is hereby amended and supplemented by adding the following:

    Between December 29, 2023 and January 18, 2024, Gilde Healthcare sold an aggregate of 230,557 shares of Common Stock of the Company in open market transactions.

    Item 5. Interest in Securities of the Issuer.

    Item 5 is hereby amended and restated in its entirety below:

    (a) According to the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on October 31, 2023, there were 20,815,635 shares of Common Stock outstanding as of October 24, 2023.

    Gilde Healthcare is the record holder of an aggregate of 1,365,743 shares of Common Stock and 2,463 options to purchase Common Stock exercisable within 60 days of January 17, 2024, which together represents beneficial ownership of approximately 6.6% of the outstanding shares of Common Stock.

    GHCIVM, as the manager of Gilde Healthcare, has the power to vote and dispose of securities held by Gilde Healthcare and may be deemed to beneficially own the securities held of record by Gilde Healthcare.

    As a result, each of the Reporting Persons may beneficially own an aggregate of 1,368,206 shares of Common Stock, or approximately 6.6% of the outstanding Common Stock.

    (b) Each Reporting Person has shared power to vote and dispose of 1,368,206 shares of Common Stock.

    (c) Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer’s securities within the past 60 days.

    (d) Only Gilde Healthcare has the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by Gilde Healthcare.

    (e) Not applicable.


    CUSIP NO. 126638105    13D    Page 7 of 9 Pages

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to the Securities of the Issuer.

    Except as referenced herein, there are no changes to the Item 6 information previously filed.

    Item 7. Materials to be Filed as Exhibits.

    There are no changes to the Item 7 information previously filed.


    CUSIP NO. 126638105    13D    Page 8 of 9 Pages

     

     

    Signatures

    After reasonable inquiry and to the best knowledge and belief of the undersigned, such person certifies that the information set forth in this Statement with respect to such person is true, complete and correct.

     

    Dated: January 19, 2024     COOPERATIEVE GILDE HEALTHCARE IV U.A.
        By: GILDE HEALTHCARE IV MANAGEMENT BV
        Its: Manager
        By:  

    /s/ Edwin de Graaf

        Name:   Edwin de Graaf
        Title:   Managing Director
        GILDE HEALTHCARE IV MANAGEMENT BV
        By:  

    /s/ Edwin de Graaf

        Name:   Edwin de Graaf
        Title:   Managing Director
        GILDE HEALTHCARE HOLDING BV
        By:  

    /s/ Edwin de Graaf

        Name:   Edwin de Graaf
        Title:   Managing Director
        MANAPOURI B.V.
        By:  

    /s/ Edwin de Graaf

        Name:   Edwin de Graaf
        Title:   Managing Partner
        MARTEMANSHURK B.V.
        By:  

    /s/ Pieter van der Meer

        Name:   Pieter van der Meer
        Title:   Managing Partner


    Annex A

    60 Day Trading History

    The following transactions were effected by Cooperatieve Gilde Healthcare IV U.A. in Common Stock during the past 60 days:

     

    Trade Date

       Amount Sold      Weighted
    Average Price
    Per Share
     

    12/21/2023

         18,386      $ 25.213  

    12/22/2023

         7,423      $ 25.171  

    12/26/2023

         124,191      $ 29.362  

    12/27/2023

         35,000      $ 30.594  

    12/28/2023

         47,722      $ 32.221  

    12/29/2023

         17,278      $ 31.734  

    01/02/2024

         33,154      $ 30.723  

    01/03/2024

         2,114      $ 30.052  

    01/04/2024

         19,394      $ 29.740  

    01/05/2024

         12,876      $ 29.359  

    01/08/2024

         19,322      $ 28.411  

    01/09/2024

         25,269      $ 28.340  

    01/10/2024

         37,871      $ 28.208  

    01/11/2024

         10,000      $ 28.133  

    01/12/2024

         4,746      $ 28.130  

    01/16/2024

         4,944      $ 28.025  

    01/17/2024

         30,310      $ 27.561  

    01/18/2024

         13,279      $ 27.401  
    Get the next $CVRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVRX

    DatePrice TargetRatingAnalyst
    5/9/2025$7.00Neutral → Underweight
    Analyst
    1/14/2025Mkt Perform → Outperform
    William Blair
    9/10/2024$14.00Overweight
    Cantor Fitzgerald
    7/11/2024$18.00 → $12.00Buy
    Lake Street
    5/1/2024$30.00 → $23.00Buy
    Craig Hallum
    5/1/2024Outperform → Mkt Perform
    William Blair
    5/1/2024$36.00 → $13.00Overweight → Neutral
    JP Morgan
    1/31/2023$20.00Buy
    Lake Street
    More analyst ratings

    $CVRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CVRx, Inc. downgraded by Analyst with a new price target

      Analyst downgraded CVRx, Inc. from Neutral to Underweight and set a new price target of $7.00

      5/9/25 8:41:10 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx, Inc. upgraded by William Blair

      William Blair upgraded CVRx, Inc. from Mkt Perform to Outperform

      1/14/25 7:51:14 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on CVRx, Inc. with a new price target

      Cantor Fitzgerald initiated coverage of CVRx, Inc. with a rating of Overweight and set a new price target of $14.00

      9/10/24 7:46:21 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CVRx Reports First Quarter 2025 Financial and Operating Results

      MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2025. Recent Highlights Total revenue for the first quarter 2025 was $12.3 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the first quarter of 2025 was $11.1 million, an increase of 14% over the prior year quarterActive implanting centers in the U.S. grew to 227, an increase of 19% since March 31, 2024Real-world e

      5/8/25 4:05:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

      MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time

      4/24/25 4:30:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Reports Preliminary First Quarter 2025 Financial Results

      MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results. "While we continue to make significant progress in driving adoption of Barostim, first quarter revenue fell short of our expectations," said Kevin Hykes, President and Chief Executive Officer of CVRx. "A core element of the commercial strategy initiated last year has been to build a world-class sales organization. As part of this effort, we brought in a number of new high-quality sales representatives in the back half of 2024 and the first quarter of 2025. We are thrilled with the lev

      4/7/25 4:05:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Nielsen Kirk G. bought $977,346 worth of shares (187,813 units at $5.20) (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/14/25 5:27:07 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • Director Jain Mudit K. bought $7,775 worth of shares (1,650 units at $4.71), increasing direct ownership by 49% to 5,050 units (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/13/25 7:12:40 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • PRES & CEO Hykes Kevin bought $24,200 worth of shares (5,000 units at $4.84), increasing direct ownership by 4% to 133,000 units (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/12/25 7:07:45 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Nielsen Kirk G. bought $977,346 worth of shares (187,813 units at $5.20) (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/14/25 5:27:07 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • Director Jain Mudit K. bought $7,775 worth of shares (1,650 units at $4.71), increasing direct ownership by 49% to 5,050 units (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/13/25 7:12:40 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • PRES & CEO Hykes Kevin bought $24,200 worth of shares (5,000 units at $4.84), increasing direct ownership by 4% to 133,000 units (SEC Form 4)

      4 - CVRx, Inc. (0001235912) (Issuer)

      5/12/25 7:07:45 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by CVRx Inc.

      10-Q - CVRx, Inc. (0001235912) (Filer)

      5/9/25 8:25:25 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CVRx, Inc. (0001235912) (Filer)

      5/8/25 4:09:03 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by CVRx Inc.

      DEF 14A - CVRx, Inc. (0001235912) (Filer)

      4/23/25 4:15:28 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care

    $CVRX
    Leadership Updates

    Live Leadership Updates

    See more

    $CVRX
    Financials

    Live finance-specific insights

    See more

    $CVRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer

      MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. "We are thrilled to welcome Robert to the CVRx executive team as we continue to expand the adoption of Barostim therapy," said Kevin Hykes, President and CEO of CVRx. "Robert is well-known and respected within the heart failure community and

      6/25/24 6:50:00 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

      Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022 MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will retire from the Company and resign his Board seat concurrent with Hykes' appointment and has agreed to consult with the Company to ensure a seamless transition. Hykes is an accomplishe

      1/31/24 8:00:00 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Appoints Industry Veteran Kevin Hykes to Board of Directors

      MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) --  CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022. "We are excited to welcome an executive with the depth of expertise of Kevin Hykes to our Board of Directors," said John Nehra, lead independent director of CVRx. "His commercial experience in accelerating the growth of novel interventional therapies and his executive acumen will prove an invaluable resource as we continue to build our b

      12/20/22 4:05:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Reports First Quarter 2025 Financial and Operating Results

      MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2025. Recent Highlights Total revenue for the first quarter 2025 was $12.3 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the first quarter of 2025 was $11.1 million, an increase of 14% over the prior year quarterActive implanting centers in the U.S. grew to 227, an increase of 19% since March 31, 2024Real-world e

      5/8/25 4:05:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

      MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time

      4/24/25 4:30:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • CVRx Reports Preliminary First Quarter 2025 Financial Results

      MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results. "While we continue to make significant progress in driving adoption of Barostim, first quarter revenue fell short of our expectations," said Kevin Hykes, President and Chief Executive Officer of CVRx. "A core element of the commercial strategy initiated last year has been to build a world-class sales organization. As part of this effort, we brought in a number of new high-quality sales representatives in the back half of 2024 and the first quarter of 2025. We are thrilled with the lev

      4/7/25 4:05:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by CVRx Inc.

      SC 13D/A - CVRx, Inc. (0001235912) (Subject)

      11/7/24 9:10:51 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CVRx Inc.

      SC 13G/A - CVRx, Inc. (0001235912) (Subject)

      11/1/24 11:05:15 AM ET
      $CVRX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by CVRx Inc. (Amendment)

      SC 13G/A - CVRx, Inc. (0001235912) (Subject)

      2/6/24 7:56:00 PM ET
      $CVRX
      Medical/Dental Instruments
      Health Care